Intermittent explosive disorder …

Emil F Coccaro MD

Epilepsy & Seizures

Updated 03.28.2018
Released 07.26.2013
Expires For CME 03.28.2021

Intermittent explosive disorder

Author: Emil F Coccaro MD

See Contributor Disclosures

Editor: C P Panayiotopoulos MD PhD

Intermittent explosive disorder

In This Article

Quick Link

Introduction

This article includes discussion of intermittent explosive disorder and episodic dyscontrol. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.

Overview

Intermittent explosive disorder, as described in the DSM-5 (04), represents the categorical expression of recurrent, problematic, impulsive aggression. Diagnostic criteria include impulsive aggressive outbursts, disproportionate to provocation, that occur at least twice weekly for 3 months for low intensity outbursts and/or at least 3 high intensity outbursts including serious physical assault on another person or destruction of property of more than trivial value. Most individuals with intermittent explosive disorder report both types of aggressive outbursts. Neurobiological studies suggest reduced central serotonergic (5-HT) function, reduced frontal-limbic grey matter, and an inverse correlation with aggression overall, and enhanced amygdala response to social threat in those with intermittent explosive disorder. Psychologically, individuals with intermittent explosive disorder display increased hostile attribution bias and negative emotional response to socially ambiguous interactions. Impulsive aggressive behavior in those with intermittent explosive disorder may be treated with 5-HT selective uptake inhibitors (eg, fluoxetine), lithium, and some other mood stabilizing agents.

Historical note and terminology

The essence of intermittent explosive disorder has been included in the Diagnostic and Statistical Manual of Mental Disorders since its inception. In 1952, “passive aggressive personality, aggressive type” was included in the DSM-1 (01) and represented the presentation of those who responded to stress and provocation with aggressive outbursts. By DSM-2 (02), this was listed as “explosive personality disorder”. By DSM-3 (03), this was changed to “intermittent explosive disorder” and represented something akin to “episodic dyscontrol” with the idea that such aggressive outbursts were caused by seizures stemming from an irritable limbic focus. However, diagnostic criteria were incompletely operationalized and the exclusion of inter-outburst aggression and/or impulsivity, as well as other diagnostic exclusions, made it appear that intermittent explosive disorder was quite rare. Psychobiological study of impulsive aggression, and the observation that some medications could reduce this behavior, led to the idea that intermittent explosive disorder was not due to seizure-like activity at a limbic focus but due to a balance of inhibitory and excitatory influences in cortico-limbic structures. Over the course of research in the past 2 decades, the idea that intermittent explosive disorder is a disorder of impulsive aggression (08) gained sufficient diagnostic validity to justify recognition and inclusion in DSM-5 (04). Although the corresponding alternative classification in ICD-10 (57) is not as well defined as in DSM-5, we expect this to change in ICD-11. Finally, there has been considerable research undertaken to differentiate children and adolescents with aggression and irritability from those with similar symptomatology but who experience bipolar disorder. This has particular relevance to child and adolescent psychiatry with expectation of the evolution of a new diagnostic entity, “disruptive mood dysregulation disorder” with aggressive episodes as part of a mood disorder, contrasted with an impulsive control disorder (36).

Clinical manifestations

Presentation and course

The DSM-5 has defined the diagnostic criteria for intermittent explosive disorder (312.34 [F63.81]) as (04):

Recurrent outbursts consequent to inability to control impulsive aggression. This can result in verbal or physical offensive behavior on average twice weekly over a three month period (without damage/destruction to property of more than trivial value or serious physical injury to others) or three outbursts causing such damage/destruction and/or serious physical injury to others over a one-year period.

Additional diagnostic criteria include:

• Disproportionate aggression relative to provocation;
• Impulsive, angry act without premeditation;
• Outbursts evoking significant consequences;
• Patient chronological age of 6 years or older;
• No better explanation for the aggressive outbursts.

These diagnostic criteria carry the caveat that the diagnosis may be concurrent with the diagnosis of attention deficit hyperactivity disorder, conduct disorder, oppositional defiant disorder, or autistic spectrum disorder if the aggressive outbursts exceed what is accepted within the criteria for these conditions and merits "independent clinical attention."

The clinical manifestations associated with intermittent explosive disorder include: rapid onset devoid of significant prodrome; episodes usually lasting less than 30 minutes duration without significant provocation; minor aggressive outbursts between more significant episodes; periodicity as defined above (twice weekly for 3 months with less serious outbursts or thrice yearly for more destructive episodes); lack of control over impulsive aggression with disproportionate provocation; impulsive or anger-based outbursts without premeditation; age 6 years or older (either chronologically or developmentally); and exclusion of those diagnosed with disruptive mood dysregulation disorder or in whom an alternative etiology is more persuasive. If impulsive aggression occurs in the context of an adjustment disorder in those aged 6 to 18 years, intermittent explosive disorder should not be diagnosed.

Because impulsive aggressive behavior appears in patients with many diagnoses, many clinicians are reluctant to make a diagnosis of intermittent explosive disorder in the presence of other psychiatric diagnoses. In fact, impulsive aggressive behavior is manifest in all humans early in life and before the onset of other psychiatric disorders. In the vast majority of people impulsive aggressive behaviors diminish over time, frequently well before adolescence (55). In the adolescent supplement to the National Comorbidity Survey Replication, lifetime DSM-4 intermittent explosive disorder by “narrow” criteria was 5.3% (44), similar to what was found in adults (31). Clinical studies suggest significant comorbidity of intermittent explosive disorder with mood disorders, anxiety disorders, and substance use disorders (09). In each case, with the exception of phobic anxiety disorders, the age of onset of intermittent explosive disorder is reported to be earlier than that of the comorbid disorder. This suggests independence of the disorders or that intermittent explosive disorder might be a risk factor for the comorbid disorder. A similar finding was found in a family history study of intermittent explosive disorder (07). Finally, some also claim that the diagnosis of intermittent explosive disorder should not be made in the presence of borderline, or antisocial, personality disorder. However, when examined empirically, levels of lifetime aggressive behavior among “borderline personality disorder/antisocial personality disorder only” individuals are markedly lower than those who also meet criteria for intermittent explosive disorder, indicating that both diagnoses should be made when criteria for both are met (08).

Prognosis and complications

Intermittent explosive disorder is a chronic condition that can begin as early as the first decade (though a diagnosis cannot be made until age 6). It peaks in the second decade and new cases rarely appear after the fourth decade. Severity of intermittent explosive disorder can vary but the average level of lifetime aggression is typically greater than 18 (n.b., maximum score for the Life History of Aggression is 25) on the life history of aggression assessment (10). By way of comparison, nonaggressive individuals without any psychiatric disorder (healthy controls) have average Life History of Aggression scores of about 5 whereas nonaggressive individuals with other mood, anxiety, and/or personality disorders (psychiatric controls) have average life history of aggression scores of about 9. Assessment of current aggressive behavior using the Overt Aggression Scale Modified for Outpatient Use yields even larger differences, with total aggression scores of about 2 for healthy controls, about 12 for nonaggressive psychiatric controls, and about 100 for individuals with intermittent explosive disorder (14).

Not surprisingly, individuals with intermittent explosive disorder experience significant psychosocial consequences as a result of recurrent, impulsive, aggressive behavior. First, global psychosocial function is reduced in intermittent explosive disorder compared with both healthy and psychiatric controls (33), as is quality of life experience even when differences in global psychosocial function are accounted for (49). Examined more closely, individuals with intermittent explosive disorder report greater dysfunction while at work and with family and friends (33). In addition, there are the primary effects of aggressive outbursts, the damage done, and the potential for litigation or criminal charges.

Clinical vignette

AB, a 31-year-old, single, Caucasian male came for evaluation because of history of several, recent, aggressive outbursts that led to his dismissal from his last 2 jobs in information technology. AB admitted to angry outbursts in response to frustration with “defects” in computer programs and with criticism from his supervisors advising him to be a “bit less detail-oriented” because his insistence on “getting it right” was making him less productive. Two weeks before evaluation AB had a substantial aggressive outburst with his boss that included screaming and threats to harm his supervisor. AB was removed by security and he was served with a temporary restraining order to stay away from his supervisor.

On exam, AB was well groomed and appeared very concerned about his current situation. He admitted to having a “temper” but said he never hurt anyone before and that he never threatened anyone before. The recent episode made him anxious about his future because, perhaps, he was getting worse. AB reported that he was always a bit anxious and that things had to be “just so” or he would become upset. He knew that his “quick temper” had led him to have difficulty retaining friendships so he sought out a career where he could work alone most of the time. He admitted to having previous periods where he was somewhat depressed but further interview revealed that he never had a full blown episode of any specific psychiatric disorder. His medical evaluation was unremarkable and there was no medical or pharmacological reason for him to be at risk for impulsive aggressive outbursts. AB admitted to more than 3 aggressive outbursts a week, though mostly not while at work. The outbursts were characterized by screaming and throwing things around. He denied ever hitting another person but did admit to breaking things worth more than $50 during his tantrums several times a year.

AB was started on a selective serotonin reuptake inhibitor and increased to maximal dose within 2 weeks. His aggressive outbursts started to decrease to about half of their original frequency in 2 months, at which point he began treatment with a clinical psychologist to do cognitive behavioral therapy focusing on his impulsive aggressive behavior. After 12 sessions he reported feeling less angry and less likely to be irritated by the things that used to “set him off”. He continued on the selective serotonin reuptake inhibitor and continued with cognitive behavioral therapy having “booster sessions” every month or 2. He was able to find work again and continues to be much improved, reporting that he only has an occasional outburst outside of work 1 year after treatment began.

Biological basis

Etiology and pathogenesis

The exact etiology of impulsive aggression in the context of intermittent explosive disorder remains to be defined, but clearly is multidetermined in nature with contributions from genetics, neurochemistry, and cortico-limbic function.

Aggression is under both genetic and environmental influence, with up to 50% of the variability in measures of aggression accounted for by genetic factors (45). Our own twin studies using aggression support this, showing genetic influence of the aggression increasing with the severity of the aggressive acts from 28% for verbal aggression to 45% for aggression against others. In addition, impulsivity is under similar genetic influence in these types of studies and the genetic correlation of impulsivity and aggression is correspondingly substantial, supporting the conceptualization of aggression as a form of dysregulation (51). Following from this, it is not surprising that intermittent explosive disorder runs in families of first-degree relatives of those with intermittent explosive disorder by about 3-fold (07).

From a psychobiological standpoint, aggression, particularly impulsive aggression, is associated with a reduction in central 5-HT function that is also observable in more distal indices of 5-HT function. For example, inverse correlations have been reported between measures of aggression and CSF 5-hydroxyindoleacetic acid (38), hormonal responses to 5-HT pharmaco-challenge (18), and platelet 5-HT transporter (5-HTT) binding (19). These findings are highly consistent with animal studies reporting inverse relationships between 5-HT and aggressive responding first reported in the literature in the 1960s. Other neurochemical systems may also be relevant in human aggression. At this time, there is preliminary data supporting positive relationships between aggression and catecholamines: norepinephrine (21), dopamine (37; 07), and other amines such as glutamate (23); peptides like vasopressin (15), substance P (22), and neuropeptide Y (20); and circulating cytokines such as interleukin-6 (54; 40; 17). There is similar data supporting an inverse relationship between aggression and oxytocin (35). However, with the exception of manipulating 5-HT as a strategy to reduce (27) or increase (06) impulsive aggression, few studies have been conducted to explore how manipulating non-5-HT systems reduces, or has no effect on, impulsive aggressive behavior in humans.

Positron emission tomographic imaging studies have extended these findings in impulsively aggressive personality disordered study participants, most of whom would meet criteria for intermittent explosive disorder. Frankle and colleagues reported reduced availability of the 5-HT transporter (5-HTT) in several cortical and subcortical regions that was significantly lowest in the anterior cingulate cortices of impulsively aggressive personality disordered individuals (28). Although another study did not replicate this finding (56) another positron emission tomography study labeling the 5-HT-2a receptor reported increased binding of 5-HT-2a receptors in the orbitofrontal cortex of impulsively aggressive personality disordered individuals (47).

Similarly, studies of individuals with intermittent explosive disorder note categorical differences in structural and functional imaging studies as would be expected from studies of aggression in general. Individuals with intermittent explosive disorder display a reduction in gray matter volume in fronto-limbic circuits (13), abnormalities in the shape of the amygdala and hippocampus (24), and reduced fractional anisotropy in the superior longitudinal fasciculus (34), all suggesting important structural deficits in critical emotion regulating areas of the brain. Despite the possibility of a smaller, less smooth amygdala, functional fMRI studies note hyperactivity of the amygdala to hostile social threat (ie, anger faces) in intermittent explosive disorder compared with heathy controls, with either unchanged or reduced activation of prefrontal cortical regions (25; 43). We found that although the amygdala exhibits a hyperactive response to anger faces, amygdala responses to induced emotion are not different in intermittent explosive disorder compared with healthy controls (24a). This suggests that heightened amygdala activity to hostile social threat may be an endophenotype for intermittent explosive disorder. Finally, we have found important differences in fMRI responses to videos displaying socially ambiguous situations in which 1 individual experiences a potentially aggressive event. In these studies we have found that individuals with intermittent explosive disorder display multiple deficits in cortico-limbic activation as a function of the different steps in social-emotional information processing (11). Specifically, compared with healthy controls, individuals with intermittent explosive disorder display reduced activation of medial prefrontal and anterior cingulate cortices when watching aggressive versus nonaggressive videos, reduced activation of dorsolateral prefrontal cortex and at the temporoparietal junction while evaluating if the person in the video was hostile in their actions, and reduced activation of superior prefrontal cortex and the periaqueductal gray when estimating how angry they would be if the potentially aggressive event happened to them.

Epidemiology

Before the advent of the DSM-4, intermittent explosive disorder was thought to “rare”. This is because the DSM criteria excluded most individuals with recurrent impulsive aggressive outbursts because intermittent explosive disorder was thought to be a disorder in which someone was otherwise “fine” but that occasionally they had extreme outbursts of aggression (eg, “Bruce Banner” vs. “The Hulk”). With DSM-4, and especially with DSM-5, intermittent explosive disorder appears to be much more common than previously thought. The National Comorbidity Study Replication reported a lifetime prevalence of DSM-4 intermittent explosive disorder in the United States of 7.3% by “broad criteria” and 5.4% by “narrow criteria,” and past year prevalence as 3.9% and 2.7%, respectively (31). Inspection of the data reveals meaningful differences between the 2 intermittent explosive disorder types, with “narrow” intermittent explosive disorder being far more severe than “broad” intermittent explosive disorder (08). “Broad” intermittent explosive disorder stipulates only 3 aggressive outbursts during a lifetime whereas “narrow” intermittent explosive disorder requires at least 3 aggressive outbursts in a single year. This prevalence rate may not be true in non-U.S. countries, however, where the lifetime estimate of DSM-4 intermittent explosive disorder appears to range from only 0.1% (ie, Nigeria) to 1.2% (ie, Columbia, South Africa) averaging 0.6% compared with 2.7% for the United States (50). Reasons for this cross-national difference are not known with any certainty but are likely related to variation in general risk factors, cultural factors that impact on willingness to disclose information about one’s own psychopathology, and other methodological factors. A separate analysis of the U.S. data suggests the lifetime rate of DSM-4 intermittent explosive disorder in the U.S. is 3.6% (12), down from the 5.4% in the original report (31). In addition, a survey study of over 5300 nondeployed army service members (Army STARRS) reported lifetime pre- and post-enlistment diagnoses of DSM-4 intermittent explosive disorder of 3.7% and 3.8%, respectively (46). Despite these data, the community rate of DSM-5 intermittent explosive disorder is not known. This is because DSM-5 criteria for intermittent explosive disorder require either low intensity but high-frequency impulsive aggressive outbursts (A1 criteria) or high intensity but low frequency outbursts (A2 criteria). Because the data instrument used in the National Comorbidity Study Replication(31) and the multinational (50) study only sought information about A2, not A1, type of impulsive aggressive outbursts, the prevalence of those meeting only the A1 criteria in the National Comorbidity Study Replication sample is unknown. New data from our own studies suggest that more than one fifth of those with current intermittent explosive disorder meet the A1 criteria only (had only frequent nondestructive/injurious outbursts) but not the A2 criteria for DSM-5 intermittent explosive disorder (Coccaro et al submitted). If so, one might estimate the lifetime prevalence of DSM-5 intermittent explosive disorder in the United States as 3.3% (50) to 4.4% (12), until another community survey is done assessing the epidemiology of DSM-5 disorders.

Differential diagnosis

Individuals who present with history of recurrent, problematic, impulsive aggressive outbursts should be assessed for any medical or other psychiatric reason for their behavior. This includes, for example, cerebral tumors, dementia, drug effects, and the like.

Those with a history of physical or emotional trauma before 20 years of are at increased risk of intermittent explosive disorder (04). Other factors relevant to such damage must be considered in the differential diagnosis. The DSM-5 stipulates that a diagnosis of intermittent explosive disorder should not be considered if the aggressive outbursts only occur within the context of another psychiatric illness. Similarly, it should not be diagnosed in children or adolescents aged 6 to 18 years if the outbursts occurred during an adjustment disorder. Other confounding diagnoses include: disruptive mood dysregulation disorder; delirium, major neurocognitive disorder, and personality change due to other medical condition (aggressive type); substance intoxication or substance withdrawal; and attention deficit hyperactivity disorder, conduct disorder, oppositional defiant disorder or autism spectrum disorder.

A number of comorbidities, which occur in conjunction with intermittent explosive disorder, are identified in DSM-5 (04) and include: depressive disorders, anxiety disorders, substance use disorders, eating disorders, and individuals with other diagnoses involving disruptive behavior (such as attention deficit hyperactivity disorder, conduct disorder, or oppositional defiant disorder). The critical issues in each of these cases is that individuals with comorbid psychiatric disorders who also meet DSM-5 criteria for intermittent explosive disorder are typically more aggressive than those with these comorbid disorders alone, in which case both disorders can be diagnosed.

References

01: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM I). Washington DC, 1952.
02: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM II). Washington DC, 1968.
03: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III). Washington DC, 1980.
04: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington DC, 2013:466-7.
05: Barratt ES, Stanford MS, Felthous AR, Kent TA. The effects of phenytoin on impulsive and premeditated aggression: a controlled study. J Clin Psychopharmacology 1997;411045-61.**
06: Berman ME, McCloskey MS, Fanning JR, Schumacher JA, Coccaro EF. Serotonin augmentation reduces response to attack in aggressive individuals. Psychol Sci 2009;20(6):714-20.** PMID 19422623
07: Coccaro EF. A family history study of intermittent explosive disorder. J Psychiatr Res 2010;44(15):1101-5. PMID 20488459
08: Coccaro EF. Intermittent Explosive Disorder as a Disorder of Impulsive Aggression for DSM-5. Am J Psychiatry 2012;169(6):577-88. PMID 22535310
09: Coccaro EF. Intermittent explosive disorder: development of integrated research criteria for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Compr Psychiatry 2011;52(2):119-25.** PMID 21295216
10: Coccaro EF, Berman ME, Kavoussi RJ. Assessment of life history of aggression: development and psychometric characteristics. Psychiatry Res 1997;73(3):147-57. PMID 9481806
11: Coccaro EF, Fanning JR, Fisher E, Couture L, Lee RJ. Social emotional information processing in adults: Development and psychometrics of a computerized video assessment in healthy controls and aggressive individuals. Psychiatry Res 2017b;248:40-7. PMID 28012305
12: Coccaro EF, Fanning JR, Lee R. Intermittent explosive disorder and substance use disorder: analysis of the National Comorbidity Study-Replication sample. J Clin Psychiatry 2017a;78(6):697-702. PMID 28252880
13: Coccaro EF, Fitzgerald DA, Lee R, McCloskey M, Phan KL. Fronto-limbic morphometric abnormalities in intermittent explosive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging 2016c;1(1):32-8. PMID 29560894
14: Coccaro EF, Harvey PD, Kupsaw-Lawrence E, Herbert JL, Bernstein DP. Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. J Neuropsychiatry Clin Neurosci 1991;3(2):S44-51. PMID 1821222
15: Coccaro EF, Kavoussi RJ, Hauger RL, Cooper TB, Ferris CF. Cerebrospinal fluid vasopressin levels: correlates with aggression and serotonin function in personality-disordered subjects. Arch Gen Psychiatry 1998;55(8):708-14. PMID 9707381
16: Coccaro EF, Lee R. Cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid: reciprocal relationships with impulsive aggression in human subjects. J Neural Trans 2010;117(2):241-8. PMID 20069438
17: Coccaro EF, Lee R, Coussons-Read M. Elevated plasma inflammatory markers in individuals with intermittent explosive disorder and correlation with aggression in humans. JAMA Psychiatry 2014;71(2):158-65. PMID 24352431
18: Coccaro EF, Lee R, Kavoussi RJ. Aggression, suicidality, and intermittent explosive disorder: serotonergic correlates in personality disorder and healthy control subjects. Neuropsychopharmacology 2010a;35(2):435-44.** PMID 19776731
19: Coccaro EF, Lee R, Kavoussi RJ. Inverse relationship between numbers of 5-HT transporter binding sites and life history of aggression and intermittent explosive disorder. J Psychiatr Res 2010b;44(3):137-42. PMID 19767013
20: Coccaro EF, Lee R, Liu T, Mathé AA. Cerebrospinal fluid neuropeptide Y-like immunoreactivity correlates with aggression in human subjects. Biol Psychiatry 2012b;72(12):997-1003. PMID 22985695
21: Coccaro E, Lee R, McCloskey MS. Norepinephrine function in personality disorder: plasma free MHPG correlates inversely with life history of aggression. CNS Spectr 2003;8(10):731-6. PMID 14712171
22: Coccaro EF, Lee R, Owens MJ, et al. Cerebrospinal fluid substance P-Like immunoreactivity correlates with aggression in personality disordered subjects. Biol Psychiatry 2012a;72(3):238-43. PMID 22449753
23: Coccaro EF, Lee R, Vezina P. Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects. J Psychiatr Res 2013;47(9):1247-53. PMID 23791397
24: Coccaro EF, Lee R, McCloskey M, Csernansky JG, Wang L. Morphometric analysis of amygdala and hippocampus shape in impulsively aggressive and healthy control subjects. J Psychiatr Res 2015a;69:80-6. PMID 26343598
25: Coccaro EF, McCloskey MS, Fitzgerald DA, Phan KL. Amygdala and orbitofrontal reactivity to social threat in individuals with impulsive aggression. Biol Psychiatry 2007;62(2):168-78. PMID 17210136
26: Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988;45(2):111-9. PMID 3276280
27: Dougherty DD, Shin LM, Alpert NM, et al. Anger in healthy men: a PET study using script-driven imagery. Biol Psychiatry 1999;46(4):466-72. PMID 10459395
28: Frankle WG, Lombardo I, New AS, et al. Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652. Am J Psychiatry 2005;162(5):915-23. PMID 15863793
29: George DT, Phillips MJ, Lifshitz M, et al. Fluoxetine treatment of alcoholic perpetrators of domestic violence: a 12-week, double-blind, randomized, placebo-controlled intervention study. J Clin Psychiatry 2011;72(1):60-5. PMID 20673556
30: Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003;28(6):1186-97. PMID 12700713
31: Kessler RC, Coccaro EF, Fava M, Jaeger S, Jin R, Walters E. The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006;63(6):669-78. PMID 16754840
32: Kim E, Bijlani M. A pilot study of quetiapine treatment of aggression due to traumatic brain injury. J Neuropsychiatry Clin Neurosci 2006;18(4):547-9. PMID 17135382
33: Kulper DA, Kleiman EM, McCloskey MS, Berman ME, Coccaro EF. The experience of aggressive outbursts in intermittent explosive disorder. Psychiatry Res 2015;225(3):710-5. PMID 25541537
34: Lee R, Arfanakis K, Evia AM, Fanning J, Keedy S, Coccaro EF. White matter integrity reductions in intermittent explosive disorder. Neuropsychopharmacology 2016;41(11):2697-703. PMID 27206265
35: Lee R, Ferris C, Van de Kar LD, Coccaro EF. Cerebrospinal fluid oxytocin, life history of aggression, and personality disorder. Psychoneuroendocrinology 2009;34(10):1567-73. PMID 19577376
36: Leibenheft E. Severe mood dysregulation, irritability, and the diagnostic boundaries of bipolar disorder in youths. Am J Psychiatry 2011;168:129-42.** PMID 21123313
37: Limson R, Goldman D, Roy A, et al. Personality and cerebrospinal fluid monoamine metabolites in alcoholics and controls. Arch Gen Psychiatry 1991;48(5):437-41. PMID 1708656
38: Linnoila M, Virkkunen M, Scheinin M, et al. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci 1983;33(26):2609-14. PMID 6198573
39: Maley JH, Alvermia JE, Vella EP, Richardson D. Deep brain stimulation of the orbitofrontal projections for the treatment of intermittent explosive disorder. Neurosurg Focus 2010;29(2):E11. PMID 20672913
40: Marsland AL, Prather AA, Petersen KL, Cohen S, Manuck SB. Antagonistic characteristics are positively associated with inflammatory markers independently of trait negative emotionality. Brain Behav Immun 2008;22(5):753-61. PMID 18226879
41: Mattes JA. Medications for aggressiveness in prison: focus on oxcarbazepine. J Am Acad Psychiatry Law 2012;40(2):234-8. PMID 22635296
42: McCloskey MS, Noblett KL, Deffenbacher JL, Gollan JK, Coccaro EF. Cognitive-behavioural therapy for intermittent explosive disorder: a pilot randomized control trial. J Consult Clin Psychol 2008;76:876-86.** PMID 18837604
43: McCloskey MS, Phan KL, Angstadt M, Fettich KC, Keedy S, Coccaro EF. Amygdala hyperactivation to angry faces in intermittent explosive disorder. J Psychiatr Res 2016;79:34-41. PMID 27145325
44: McLaughlin KA, Green JG, Hwang I, Sampson NA, Zaslavsky AM, Kessler RC. Intermittent explosive disorder in the National Comorbidity Survey Replication Adolescent Supplement. Arch Gen Psychiatry 2012;69(11):1131-9. PMID 22752056
45: Miles DR, Carey G. Genetic and environmental architecture of human aggression. J Pers Soc Psychol 1997;72(1):207-17. PMID 9008382
46: Nock MK, Sein MB, Heeringa SG, et al. Prevalence and correlates of suicidal behavior among soldiers: results from the Army Study to Assess Risk and Resilience in Service members (Army STAARS). JAMA Psychiatry 2014;71(5):514-22. PMID 24590178
47: Rosell DR, Thompson JL, Slifstein M, et al. Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients. Biol Psychiatry 2010;67(12):1154-62. PMID 20434136
48: Rosenheck RA, Leslie DL, Sindelar JL, et al. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Arch Gen Psychiatry 2007;64(11):1259-68. PMID 17984395
49: Rynar L, Coccaro EF. Psychosocial impairment in DSM-5 intermittent explosive disorder. Psychiatry Res 2018;264:91-5. PMID 29627702
50: Scott KM, Lim CC, Hwang I, et al. The cross-national epidemiology of DSM-IV intermittent explosive disorder. Psychol Med 2016;46(15):3161-72. PMID 27572872
51: Seroczynski AD, Bergeman CS, Coccaro EF. Etiology of the impulsivity/aggression relationship: genes or environment? Psychiatry Res 1999;86(1):41-57. PMID 10359481
52: Sheard MH, Marini JL, Bridges CI, Wagner E. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976;133(12):1409-13. PMID 984241
53: Silva H, Iturra P, Solari A, et al. Fluoxetine response in impulsive-aggressive behavior and serotonin transporter polymorphism in personality disorder. Psychiatr Genet 2010;20(1):25-30. PMID 20010449
54: Suarez EC. Joint effect of hostility and severity of depressive symptoms on plasma interleukin-6 concentration. Psychosom Med 2003;65(4):523-7. PMID 12883100
55: Tremblay RE. Early development of physical aggression and early risk factors for chronic physical aggression in humans. In: Miczek K, Meyer-Lindenberg A, editors. Neuroscience of aggression. Current topics in behavioral neurosciences, volume 17. Berlin: Springer, Heidelberg, 2013.**
56: van de Giessen E, Rosell DR, Thompson JL, et al. Serotonin transporter availability in impulsive aggressive personality disordered patients: a PET study with [11C]DASB. J Psychiatr Res 2014;58:147-54. PMID 25145808
57: World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Switzerland, 1990.

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Emil F Coccaro MD

Dr. Coccaro of The University of Chicago received consulting fees from Azevan and Avainir.
See Profile

Editor

C P Panayiotopoulos MD PhD

Dr. Panayiotopoulos of St. Thomas' Hospital had no relevant financial relationships to disclose.
See Profile

Former Authors

Roy G Beran MD (original author)

Patient Profile

Age range of presentation: 02-05 years

06-12 years

13-18 years

19-44 years

45-64 years

65+ years
Sex preponderance: male>female, >1:1
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Intermittent explosive disorder

Associated Disorders

attention deficit hyperactivity disorder
autistic spectrum disorder
conduct disorder
oppositional defiant disorder

Differential Diagnosis

cerebral tumors
dementia
drug effects
postconcussion psychosis with delirium
temporal lobe
- hypothalamic lesions
- frontal cortical lesions
- history of physical or emotional trauma before 20 years
- disruptive mood dysregulation disorder
- paranoid personality disorder
- obsessive-compulsive personality disorder
- antisocial personality disorder
- borderline personality disorder
- personality change due to other medical condition (aggressive type)
- substance intoxication or substance withdrawal
- attention deficit hyperactivity disorder
- conduct disorder
- oppositional defiant disorder
- autism spectrum disorder
- depressive disorders
- anxiety disorders
- antisocial personality disorders
- borderline personality disorders
- other diagnoses involving disruptive behavior

Intermittent explosive disorder …

Intermittent explosive disorder

Introduction

Overview

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

Epileptic lesions due to malformation of cortical development

Epileptic spasms

Sleep and epilepsy

Neocortical temporal lobe seizures

Intermittent explosive disorder

Introduction

Overview

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

Epileptic lesions due to malformation of cortical development

Epileptic spasms

Sleep and epilepsy

Neocortical temporal lobe seizures

This is an article preview.
Start a Free Account
to access the full version.